{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=14", "query": { "intervention": "Arm 1- Dose Escalation", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 959, "total_pages": 96, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:16:03.486Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02942264", "title": "Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain Tumor", "Astrocytoma", "Astroglioma", "Glioblastoma", "Gliosarcoma" ], "interventions": [ { "name": "Zotiraciclib (TG02)", "type": "DRUG" }, { "name": "Temozolomide (TMZ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2016-12-14", "completion_date": "2020-08-26", "has_results": true, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-11-15T12:16:03.486Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02942264" }, { "nct_id": "NCT04933617", "title": "Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Burkitt Lymphoma", "High-grade B-cell Lymphoma", "T-cell/Histocyte-rich Large B-cell Lymphoma", "Diffuse Large B-Cell Lymphoma (DLBCL)", "Germinal Center B-cell Type (GCB)" ], "interventions": [ { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Copanlisib", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "ECHO", "type": "DIAGNOSTIC_TEST" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI Brain", "type": "DIAGNOSTIC_TEST" }, { "name": "18F-FDG - PET", "type": "DIAGNOSTIC_TEST" }, { "name": "CT Scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Lumbar Puncture (LP)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-03-24", "completion_date": "2023-11-30", "has_results": true, "last_update_posted_date": "2024-07-09", "last_synced_at": "2026-11-15T12:16:03.486Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04933617" }, { "nct_id": "NCT00560391", "title": "Dasatinib in Combination With Revlimid (and Dexamethasone)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg", "type": "DRUG" }, { "name": "Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg", "type": "DRUG" }, { "name": "Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg", "type": "DRUG" }, { "name": "Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg", "type": "DRUG" }, { "name": "Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2008-05", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2016-08-04", "last_synced_at": "2026-11-15T12:16:03.486Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00560391" }, { "nct_id": "NCT03381274", "title": "Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Oleclumab", "type": "BIOLOGICAL" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "AZD4635", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 43, "start_date": "2018-05-08", "completion_date": "2026-11-06", "has_results": true, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-11-15T12:16:03.486Z", "location_count": 9, "location_summary": "La Jolla, California • San Francisco, California • Aurora, Colorado + 6 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03381274" }, { "nct_id": "NCT05947474", "title": "ORB-011 In Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Cancer" ], "interventions": [ { "name": "ORB-011", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orionis Biosciences Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2023-08-21", "completion_date": "2026-05-29", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-11-15T12:16:03.486Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Houston, Texas", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05947474" }, { "nct_id": "NCT01835197", "title": "First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PF-04965842", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 79, "start_date": "2013-05", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-06-20", "last_synced_at": "2026-11-15T12:16:03.486Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01835197" }, { "nct_id": "NCT00907166", "title": "A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer", "Pancreatic Cancer", "Pancreatic Carcinoma" ], "interventions": [ { "name": "CPI-613", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cornerstone Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 6, "start_date": "2009-05", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2017-03-21", "last_synced_at": "2026-11-15T12:16:03.486Z", "location_count": 2, "location_summary": "The Bronx, New York • Dallas, Texas", "locations": [ { "city": "The Bronx", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00907166" }, { "nct_id": "NCT05929235", "title": "A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Urothelial Carcinoma", "Oral Drug Administration", "Open Label" ], "interventions": [ { "name": "FX-909", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA ®)", "type": "DRUG" }, { "name": "KEYTRUDA ®( Pembrolizumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Flare Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2023-08-24", "completion_date": "2028-01-30", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-11-15T12:16:03.486Z", "location_count": 12, "location_summary": "San Francisco, California • New Haven, Connecticut • Miami, Florida + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05929235" }, { "nct_id": "NCT06333041", "title": "Study of Cannabidiol in Sanfilippo Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Sanfilippo Syndrome", "Mucopolysaccharidosis III" ], "interventions": [ { "name": "Epidiolex", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 35, "start_date": "2026-04-01", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-11-15T12:16:03.486Z", "location_count": 1, "location_summary": "Torrance, California", "locations": [ { "city": "Torrance", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06333041" }, { "nct_id": "NCT04643002", "title": "Isatuximab in Combination With Novel Agents in RRMM - Master Protocol", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Plasma Cell Myeloma Refractory" ], "interventions": [ { "name": "Isatuximab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Pegenzileukin", "type": "DRUG" }, { "name": "SAR439459", "type": "DRUG" }, { "name": "Belumosudil", "type": "DRUG" }, { "name": "Evorpacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 258, "start_date": "2021-01-25", "completion_date": "2028-04-20", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-11-15T12:16:03.486Z", "location_count": 5, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04643002" } ] }